MENA 2024 Recordings-Checkpoint Inhibitor Related Endocrinopathies

Checkpoint Inhibitor Related Endocrinopathies - Dr. Afreen Shariff_1

Video Transcription

Video Summary

In this session, the speaker discusses the connection between checkpoint inhibitors used in oncology and endocrine toxicities, emphasizing the importance of understanding how these mechanisms work. The session covers several areas: hypothyroidism as a leading toxicity, the effects of CTLA-4 and PD-1/PD-L1 treatments, and how these can affect the pituitary and thyroid glands. Clinical cases are used to illustrate immune-related side effects, including hypothyroidism, thyroiditis, and type 1 diabetes, with a focus on diagnosis, management, and patient care. The speaker stresses timely lab work for proper diagnosis and understanding of these conditions. The session ends by underscoring the need for a nuanced and empathetic approach to patient care, especially considering the psychological impact of chronic conditions resulting from cancer treatments. The talk encourages engagement in ongoing research and guidelines development in the field of oncoendocrinology.

Keywords

checkpoint inhibitors

endocrine toxicities

hypothyroidism

immune-related side effects

oncoendocrinology

patient care